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clear, over the past 15 years, that 100 mg per day is suboptimal for
the majority of patients. An increase in the CoQ 10 plasma level,
in the study by Watson et al., from 903 6 345 to 2,029 6 856
nmol/liter, converts roughly to a baseline level of 0.8 mg/ml up to
a treatment value of 1.7 mg/ml. Optimal improvement in myocar-
dial function in our own patients did not occur until we attained
blood CoQ 10 levels .2.0 mg/ml, with average blood level of 2.9
mg/ml, on an average dose of 240 mg of CoQ 10 per day (7,8).
Furthermore, it has also been our observation that maximal myocar-
dial function improvement with CoQ 10 supplementation is rarely
observed at three months, but can be achieved at six to 12 months.
In summary, Watson et al. are to be commended for their
efforts, for it is a difficult, poorly funded and often thankless task
to evaluate any natural and nonpatentable substance. I am hopeful
that these investigators and others will move forward to further our
understanding of this remarkable nutrient, which, for many of us
out here in the trenches of patient care, is rapidly showing itself to
be a safe and effective addition to our therapeutic armamentarium.
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We thank Dr. Langsjoen for his interest in our report. He believes
that treatment with 100 mg/day of coenzyme Q 10 may be
inadequate and administered too late in the course of heart failure.
In contrast, 11 of 15 studies, including his own (1), of coenzyme
Q 10 in heart failure used #100 mg/day, and all but one purported
to provide clinical benefit with this dose. He also cites uncontrolled
observations (2) that an improvement in New York Heart Asso-
ciation functional class was associated with a higher daily dose of
240 mg (range 75 to 600) and suggests that early in the course of
idiopathic dilated cardiomyopathy, patients may respond to treat-
ment with coenzyme Q 10 (3). We wonder whether the almost
normal baseline left ventricular ejection fraction of 44% of patients
early in the course of their disease raises the possibility that for
some of them myocardial dysfunction might have been transient,
perhaps due to myocarditis. We took care to ensure that our
patients had established chronic cardiac failure. Langsjoen’s group
(3) also employed 100 mg/day of coenzyme Q 10, but more
importantly, they used impedance cardiography and systolic time
indexes, measurements of left ventricular systolic function that
were perhaps appropriate 15 years ago but might now be consid-
ered imprecise and obsolete.
We agree that a large, well-conducted and long-term trial of
coenzyme Q 10 would resolve any remaining uncertainties regard-
ing the efficacy of this agent. At this time, there are no clear data
proving its therapeutic effect in heart failure. Therefore, until there
is objective contemporary evidence of improvement in myocardial
function or survival, it will remain an unproven “alternative”
therapy for patients with heart failure. Sadly, as Langsjoen points
out, it is difficult to fund and conduct large trials of a “natural and
nonpatentable substance” such as coenzyme Q 10.
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Is the Lower Mortality in Patients
Treated With Aspirin and Angiotensin-
Converting Enzyme Inhibitors Due
to Decreased Norepinephrine Release?
We read with great interest the article by Leor et al. (1) supporting
the use of aspirin in patients with coronary artery disease treated
with angiotensin-converting enzyme (ACE) inhibitors. Their
study challenges the old tenet that aspirin may prevent the
cardioprotective effects of ACE inhibitors. Because ACE inhibi-
tors prolong bradykinin’s half-life, their cardioprotective effects
have been traditionally attributed to the antithrombotic and
vasodilating actions of prostacyclin released from the endothelium
by bradykinin (2). Evidence from our laboratory, however, sup-
ports the new findings of Leor et al. (1). We have recently
demonstrated that bradykinin is generated not only by the endo-
817JACC Vol. 35, No. 3, 2000 Letters to the Editor
March 1, 2000:815–23
thelium, but also by cardiac sympathetic nerve endings (3). This
promotes norepinephrine release in myocardial ischemia, thus
contributing to reperfusion arrhythmias (4). Bradykinin-induced
norepinephrine release in the heart is potentiated by cyclooxygen-
ase products (5). Because aspirin inhibits cyclooxygenase, one
would expect aspirin to diminish the bradykinin-induced, norepi-
nephrine release from cardiac adrenergic terminals. Indeed, we
have found this to be the case with indomethacin, another
cyclooxygenase inhibitor (5). Endothelial dysfunction is known to
occur in atherosclerotic coronary artery disease, myocardial isch-
emia and heart failure (6,7). Therefore, in these disease states, the
prostacyclin- and nitric-oxide–mediated endothelium-dependent
cardioprotective effects of bradykinin are likely to be attenuated,
and the deleterious effects of bradykinin-induced norepinephrine
release predominate. In fact, coronary arteries with dysfunctional
endothelium are hypersensitive to the vasoconstricting effects of
catecholamines (8). Thus, the improved survival demonstrated by
Leor et al. (1) may be due to an aspirin-induced reduction of
norepinephrine release within the heart. Indeed, in the Evaluation
of Losartan in the Elderly (ELITE) study (9), plasma norepineph-
rine was found to be increased in patients treated with the ACE
inhibitor captopril, but decreased in those treated with the angiotensin
receptor antagonist losartan. Increased plasma norepinephrine is
associated with a greater risk of cardiovascular morbidity and mortality
(10). In the ELITE study, patients taking captopril had a higher
mortality rate than those taking losartan (9). Accordingly, decreased
norepinephrine release could well be an important mechanism asso-
ciated with the lower mortality found by Leor et al. (1) in patients
treated with ACE inhibitors and aspirin in combination.
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We thank Levi et al. for their thoughtful comments. They
proposed a fresh explanation to our clinical observation (1).
Although previous data suggest a negative interaction between
aspirin and angiotensin-converting enzyme (ACE) inhibitors (2),
Levi et al. propose a “positive” interaction. We (1) and others (2)
were not aware of the mechanism proposed by Levi et al. They
suggest that bradykinin facilitates norepinephrine release from
cardiac sympathetic nerves during ischemia, and this effect is
potentiated by ACE inhibition (3,4). Aspirin might attenuate
bradykinin-mediated norepinephrine release from nerve endings
during myocardial ischemia. A reduction in plasma norepinephrine
might be beneficial owing to the deleterious effects of norepineph-
rine on the heart. Thus, aspirin may prevent one of the adverse
effects of bradykinin during myocardial ischemia. The mechanism
proposed by Levi et al. to explain our findings is unique and attractive,
but is derived from an isolated guinea pig heart model and specimens
of the human right atrium. Thus, these exciting findings need
confirmation in a clinical trial that will also evaluate the appropriate
dose of aspirin in patients treated with ACE inhibitors.
The neurohormonal activation in patients with heart failure or
myocardial ischemia is complex and sometimes contradicts our
conventional understanding. For example, we are disappointed by
the preliminary results of the recent Moxonidine Congestive Heart
Failure Trial (MOXCON) study (5). The study was terminated
early, and the investigators failed to confirm the hypothesis that a
reduction in plasma norepinephrine by moxonidine can reduce
mortality in patients with heart failure.
Data derived from the Evaluation of Losartan in the Elderly
(ELITE-2) study, which compared mortality in patients treated with
captopril versus losartan, and data from the Warfarin-Antiplatelet
Trial Chronic Heart Failure (WATCH) trial, which evaluates aspirin,
clopidogrel or warfarin in patients with heart failure, may help to
clarify the controversy surrounding the relation between aspirin and
ACE inhibitors. Until then, on the basis of our observation (1) and
the findings of Levi et al. (3,4), we suggest that administration of low
dose aspirin to patients taking ACE inhibitors is safe and may have an
additive beneficial effect during myocardial ischemia.
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